ProfileGDS5678 / 1454831_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 92% 91% 90% 91% 91% 91% 90% 88% 91% 91% 91% 90% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4162791
GSM967853U87-EV human glioblastoma xenograft - Control 27.7668692
GSM967854U87-EV human glioblastoma xenograft - Control 37.5355791
GSM967855U87-EV human glioblastoma xenograft - Control 47.4750890
GSM967856U87-EV human glioblastoma xenograft - Control 57.467891
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1967991
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.1402491
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1547390
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8403288
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.421891
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.456991
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5058691
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1543890
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4151691